PS-C06-11: IRISIN ASSOCIATION WITH NON DIPPER HYPERTENSION DEVELOPMENT IN OBESE PATIENTS WITH CORONARY ARTERY DISEASE

Abstract

Objective: Recent investigations showed that irisin, as a possible inflammatory marker, can be closely related to heart function, vessels tone regulation and possible development of arterial hypertension HTN. The purpose of the work was to study the relationship between irisin and the development of non dipper hypertension in obese patients with coronary artery disease CAD. Design and method: 97 obese hypertensive patients with CAD were enrolled into the study. CAD was presented as chronic coronary syndrome CCS according to 2019 ESC Guidelines, essential HTN as systolic blood pressure SBP ≧ 140 mmHg and or diastolic blood pressure DBP ≧ 90mmgHg. Obesity was assessed as body mass index BMI ≧ 30 kg per m2 according to WHO criteria. The mean age of participants was 53.61 ± 4.88 years. Patients were divided into 2 groups. The first one was with dipper HTN, n 46, and the second one with non dipper HTN, n 51. Dippers were established by Holter monitoring. Serum irisin levels were measured by ELISA. Results: It was found that irisin levels were significantly lower in non dipper hypertensive subjects compared with dippers 125.72 ± 15.09 vs 141.53 ± 21.84 ng per mL, p < 0.001. Irisin has a negative correlation with SPR r = 0.29, p < 0.01, and after adjusted for age, sex and BMI it remained a significant link between irisin and SBP, r = 0.21, p = 0.044. In multivariate logistic regression analysis of the irisin odds ratio OR 0.859, 95 per cent Confidence Interval 0.471 to 0.993, p < 0.001 was found to be independent predictors for non dipper hypertension in obese patients with CCS. Conclusions: This study shows that decreased irisin levels are significantly associated with the development of non dipper hypertension in obese patients with coronary artery disease.